Alzheimer’s Association International Conference 2012 (AAIC)
July 2012
Dr. Dana Hilt Presents Positive EVP-6124 Phase 2b Trial Results in Alzheimer’s Disease at AAIC 2012 Press Conference
Watch Press Briefing
View Presentation

November 2011
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

ICAD 2009 Conference
Vienna, Austria
July 11-16, 2009
Putative gamma secretase modulators lower Aβ42 in multiple in vitro and in vivo models. EVP-6124 - Safety, Tolerability and Cognitive Effects of a Novel α7 Nicotinic Receptor Agonist in Alzheimer’s Disease Patients on Stable Donepezil or Rivastigmine Therapy